2014
DOI: 10.1586/17474086.2013.876356
|View full text |Cite
|
Sign up to set email alerts
|

Perspectives on the impact of JAK-inhibitor therapy upon inflammation-mediated comorbidities in myelofibrosis and related neoplasms

Abstract: Chronic inflammation is suggested to contribute to the Philadelphia-chromosome-negative myeloproliferative neoplasm (MPN) disease initiation and progression, as well as the development of premature atherosclerosis and may drive the development of other cancers in MPNs, both nonhematologic and hematologic. The MPN population has a substantial comorbidity burden, including cerebral, cardiovascular, pulmonary, abdominal, renal, metabolic, skeletal, autoimmune, and chronic inflammatory diseases. This review descri… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
46
0

Year Published

2014
2014
2016
2016

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 41 publications
(46 citation statements)
references
References 94 publications
0
46
0
Order By: Relevance
“…The potent efficacy of this combination therapy in our patient may be explained by several mechanisms [1]. Firstly, using Rux with a half-life of approximately 3 h may leave a time-window of a several hours daily in which efficient IFN-signaling is possible.…”
Section: Discussionmentioning
confidence: 95%
“…The potent efficacy of this combination therapy in our patient may be explained by several mechanisms [1]. Firstly, using Rux with a half-life of approximately 3 h may leave a time-window of a several hours daily in which efficient IFN-signaling is possible.…”
Section: Discussionmentioning
confidence: 95%
“…The reasons for the survival advantage observed with ruxolitinib cannot be addressed with these data but may be due to the number of benefits of treatment in terms of spleen size reduction, 25 alleviation of cytokine-driven symptoms 8, 9 and inflammation, 30 improvement of overall nutritional status, 10 and reduced fibrosis in some patients. 31 Although several important baseline patient and clinical characteristics have been shown to be prognostic for worse survival in the currently used risk stratification systems (age >65 years, constitutional symptoms, hemoglobin <10 g/dl, white blood cell count >25 × 10 9 /l and circulating blasts ⩾1%) 5, 32 and in a pooled analysis of the COMFORT data sets (baseline spleen volume, male sex, primary MF and lower platelet count), 25 these characteristics appear not to have the same prognostic significance in the context of ruxolitinib treatment.…”
Section: Discussionmentioning
confidence: 99%
“…Treatment with ruxolitinib reduces levels of inflammatory cytokines, including IL-6 and TNF-a that are commonly elevated in MF [61,62]. Due to the reduction in the level of inflammatory mediators during ruxolitinib treatment, the potential of reducing osteosclerosis and osteoporotic fractures exists [63]. However, to our knowledge, this has not been studied.…”
Section: Jak Inhibitorsmentioning
confidence: 99%